RICHARD ZAWISLAK: Open Payments
NPI 1265807440 · BUFFALO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,841 in 16 payments from 9 companies in 2025. Trend: 2023 $4,330 · 2024 $1,503 · 2025 $1,841
Food & beverage: $1,841
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $489 |
| Vanda Pharmaceuticals Inc. | 2 | $250 |
| Teva Pharmaceuticals USA, Inc. | 2 | $236 |
| Axsome Therapeutics, Inc. | 2 | $236 |
| Otsuka America Pharmaceutical, Inc. | 2 | $145 |
| Collegium Pharmaceutical, Inc. | 1 | $125 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| Gilead Sciences, Inc. | 1 | $123 |
| Alkermes, Inc. | 1 | $111 |
Products named: CAPLYTA, FANAPT, Auvelity, Jornay PM, REXULTI, AUSTEDO XR, COBENFY, Epclusa.
Industry payments across NY — which companies pay providers there.
